S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)
S&P 500   4,568.14 (-0.04%)
DOW   36,130.70 (-0.20%)
QQQ   386.23 (-0.02%)
AAPL   193.04 (+1.91%)
MSFT   371.46 (+0.63%)
META   317.59 (-0.76%)
GOOGL   130.55 (+0.99%)
AMZN   146.71 (+1.29%)
TSLA   238.34 (+1.17%)
NVDA   462.34 (+1.59%)
NIO   7.41 (+1.23%)
BABA   72.46 (-0.78%)
AMD   118.01 (-0.47%)
T   17.28 (+3.72%)
F   10.63 (-0.65%)
MU   73.63 (-0.89%)
CGC   0.66 (-12.80%)
GE   120.43 (-0.91%)
DIS   90.52 (-1.62%)
AMC   7.06 (-5.74%)
PFE   29.21 (-0.24%)
PYPL   57.42 (-4.06%)
XOM   100.95 (-1.44%)

Clinuvel Pharmaceuticals Stock Price, News & Analysis (OTCMKTS:CLVLY)

$11.17
-0.63 (-5.34%)
(As of 12/4/2023 ET)
Compare
Today's Range
$11.17
▼
$11.64
50-Day Range
$8.88
▼
$12.06
52-Week Range
$8.76
▼
$19.98
Volume
505 shs
Average Volume
3,953 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort Interest

CLVLY stock logo

About Clinuvel Pharmaceuticals Stock (OTCMKTS:CLVLY)

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.

CLVLY Stock Price History

CLVLY Stock News Headlines

December 4, 2023 | americanbankingnews.com
Short Interest in Clinuvel Pharmaceuticals Limited (OTCMKTS:CLVLY) Increases By 14.3%
December 2, 2023 | morningstar.com
Clinuvel Pharmaceuticals Ltd ADR CLVLY
December 5, 2023 | DTI Trader (Ad)
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
October 31, 2023 | nasdaq.com
Clinuvel Pharmaceuticals Ltd - ADR (CLVLY) Price Target Increased by 18.27% to 21.08
October 5, 2023 | finance.yahoo.com
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years ago
September 1, 2023 | msn.com
Clinuvel Pharmaceuticals (CLVLF) Price Target Increased by 12.19% to 18.70
May 3, 2023 | finance.yahoo.com
Could The Market Be Wrong About Clinuvel Pharmaceuticals Limited (ASX:CUV) Given Its Attractive Financial Prospects?
May 1, 2023 | msn.com
Some Patients With a Rare Disease Face Hurdles Getting the Only Treatment
December 5, 2023 | Edge On The Street (Ad)
U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
March 30, 2023 | finance.yahoo.com
Clinuvel Pharmaceuticals (ASX:CUV) shareholders have earned a 14% CAGR over the last five years
March 1, 2023 | finance.yahoo.com
Analysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS Numbers
March 1, 2023 | finance.yahoo.com
CLINUVEL Launches CYACÊLLE, Next Generation Solar Care
February 25, 2023 | msn.com
Why Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinking
February 24, 2023 | finance.yahoo.com
Clinuvel Pharmaceuticals First Half 2023 Earnings: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)
February 24, 2023 | finanznachrichten.de
Clinuvel Pharmaceuticals Limited: Global SCENESSE demand drives increased CLINUVEL revenues, earnings
February 23, 2023 | finance.yahoo.com
Global SCENESSE® demand drives increased CLINUVEL revenues, earnings
February 2, 2023 | finanznachrichten.de
Clinuvel Pharmaceuticals Limited: CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
January 15, 2023 | finance.yahoo.com
CLINUVEL Trial Results Show Drug Reduces DNA Damage
September 19, 2022 | finance.yahoo.com
Clinuvel Pharmaceuticals' (ASX:CUV) earnings growth rate lags the 25% CAGR delivered to shareholders
June 17, 2022 | seekingalpha.com
CLVLY Clinuvel Pharmaceuticals Limited
May 16, 2022 | finance.yahoo.com
Do Insiders Own Lots Of Shares In Clinuvel Pharmaceuticals Limited (ASX:CUV)?
May 10, 2022 | finance.yahoo.com
CLINUVEL progresses vitiligo treatment program
April 29, 2022 | stockhouse.com
Letter to shareholders from CLINUVEL's CEO
April 29, 2022 | finance.yahoo.com
Letter to shareholders from CLINUVEL’s CEO
April 12, 2022 | finance.yahoo.com
Clinuvel Pharmaceuticals' (ASX:CUV) investors will be pleased with their solid 139% return over the last five years
February 23, 2022 | seekingalpha.com
Clinuvel Pharmaceuticals reports 1H results
December 3, 2021 | finance.yahoo.com
What Is The Ownership Structure Like For Clinuvel Pharmaceuticals Limited (ASX:CUV)?
See More Headlines
Receive CLVLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/2 Dividend
9/07/2023
Dividend Payable
10/02/2023
Today
12/05/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CLVLY
CUSIP
N/A
CIK
1290877
Web
www.clinuvel.com
Phone
(139) 660-4900
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Philippe Jacques Wolgen M.B.A. (Age 60)
    M.D., CEO, MD & Director
    Comp: $1.83M
  • Mr. Darren Michael Keamy B.Com. (Age 50)
    CPA, CFO & Company Secretary
    Comp: $273.12k
  • Dr. Dennis J. Wright
    Chief Scientific Officer
  • Mr. Lachlan Hay
    Director of Global Operations
  • Mr. Malcolm Bull
    Head of Australian Operations & Investor Relations

Key Competitors

View All Competitors














CLVLY Stock Analysis - Frequently Asked Questions

How have CLVLY shares performed in 2023?

Clinuvel Pharmaceuticals' stock was trading at $14.7350 on January 1st, 2023. Since then, CLVLY shares have decreased by 24.2% and is now trading at $11.17.
View the best growth stocks for 2023 here.

Are investors shorting Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,200 shares, an increase of 14.3% from the October 31st total of 2,800 shares. Based on an average daily volume of 1,500 shares, the short-interest ratio is presently 2.1 days.
View Clinuvel Pharmaceuticals' Short Interest.

How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals?

Clinuvel Pharmaceuticals declared a dividend on Wednesday, August 30th. Stockholders of record on Friday, September 8th will be given a dividend of $0.0283 per share on Monday, October 2nd. The ex-dividend date is Thursday, September 7th. This is an increase from the stock's previous dividend of $0.02.
Read our dividend analysis for CLVLY.

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:CLVLY) was last updated on 12/5/2023 by MarketBeat.com Staff

My Account -